Quick Facts

• May assist in the alleviation of pain associated with joint conditions.
• Used for the management of discomfort linked to inflammation.
• Employed in the care plan for certain forms of arthritis.

Zerodol is indicated for the symptomatic treatment of various conditions associated with pain and inflammation. Its primary therapeutic domains include assisting in the overall management of symptoms related to chronic joint and bone disorders.

Healthcare providers may utilize this medication as part of the care strategy for individuals with specific inflammatory conditions of the joints. This can include helping to mitigate discomfort and joint stiffness that are characteristic of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Additionally, it is used for the short-term relief of mild to moderate pain that may arise from other causes.

The therapeutic goal is to support an individual's mobility and overall quality of life by addressing the discomfort associated with these conditions. It is not intended to modify the underlying disease progression.

Zerodol (Ketorolac Tromethamine) is authorized for use only in a highly restricted population, primarily adults, and for a short-term duration not exceeding five total days of combined therapy. Regulatory documents define stringent exclusions based on a patient’s health stability, age, and physiological status.

Eligibility Status	Excluded Populations (Formal Contraindications)
Absolute Contraindication	Active peptic ulcer disease or history of GI bleeding/perforation
Absolute Contraindication	Advanced renal impairment or risk of renal failure due to volume depletion
Absolute Contraindication	Confirmed cerebrovascular bleeding, hemorrhagic diathesis, or high bleeding risk
Absolute Contraindication	Severe heart failure, severe hepatic failure, or known NSAID hypersensitivity
Prohibited Status	Pregnancy, labor, delivery, and lactation

Eligibility Restrictions

Age-Related Rules: Use is not established for pediatric patients younger than 17 years. Older adults (65 years and over) are subject to a reduced maximum daily dose and require special caution.

Condition-Based Rules: Patients with mild to moderate renal impairment must use a lower dosage range. The medicine is contraindicated for the treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and must not be used concurrently with other NSAIDs or aspirin.

Official Interaction Restrictions and Prohibitions

The regulatory profile for Ketorolac Tromethamine (Zerodol) establishes mandatory restrictions primarily driven by the risks of cumulative systemic toxicity and altered drug exposure.

Formally Contraindicated Combinations

Co-administration is formally prohibited with several medicinal products due to specific interaction mechanisms documented in regulatory labeling:

• Probenecid is contraindicated because it significantly reduces Zerodol's renal clearance, resulting in dangerously high plasma concentrations.
• Lithium salts are contraindicated as Zerodol decreases Lithium's renal clearance, leading to increased systemic exposure of Lithium.
• Aspirin or any other NSAID is prohibited due to the cumulative and heightened risk of serious gastrointestinal ulceration and renal toxicity.

High-Risk Exposure and Pharmacodynamic Interactions

Specific interactions require caution due to an increase in adverse event risk or loss of co-administered drug efficacy:

• Anticoagulants (e.g., Warfarin) are associated with a substantial increase in the risk of hemorrhage due to Zerodol's additive anti-platelet effect.
• Zerodol reduces the renal clearance of Methotrexate, resulting in increased plasma Methotrexate levels and potential toxicity.
• Interactions with Diuretics, ACE Inhibitors, and ARBs may reduce their blood pressure-lowering effects and increase the risk of renal deterioration.

Timing and Population Notes

Zerodol's total systemic use (oral, injectable, or nasal) must not exceed a maximum cumulative duration of five days.

A high-fat food meal may delay the peak plasma concentration of the oral tablet, although the total amount absorbed is unchanged. Regulatory information highlights that elderly patients may experience slower clearance, increasing their susceptibility to all dose-related interactions.

Molecular Mechanism: Inhibition of Cyclooxygenase Enzymes

The mechanism of action for Ketorolac (Zerodol) centers on the specific, non-selective, and reversible inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking the active sites of these enzymes, the drug fundamentally suppresses the conversion of arachidonic acid into prostaglandins—the key chemical mediators involved in inflammation and nociception. This targeted molecular interference is the basis for the drug's resulting physiological effects.

---

Dual Action on Nociceptive Signaling

The reduction in prostaglandin synthesis simultaneously impacts multiple physiological pathways. Peripherally, fewer prostaglandins are available to sensitize local pain receptors, which reduces the magnitude of signals generated at the site of injury. Centrally, the drug modulates nociceptive processing within the spinal cord and brain. This combined peripheral and central anti-nociceptive mechanism contributes to the modulation of the body's nociceptive signaling.

---

Consequential Impact on Hemostasis

The non-selective nature of the enzyme inhibition inherently extends to the COX-1 found in platelets. This temporary action prevents the synthesis of Thromboxane A2 ( TXA2), a crucial molecule for platelet aggregation. The resulting biological change means the mechanism affects the body's ability to initiate the immediate phase of blood clotting, which is a functional consequence of the non-selective inhibition.

Zerodol (Ketorolac Tromethamine) is administered using a fixed, short-term protocol encompassing the route, dose, frequency, and maximum duration. This medicine is primarily used as a parenteral (injectable) product, with the oral form serving only as continuation treatment.

---

Official Routes, Dosing, and Duration

The medicine is approved for Intravenous (IV) injection/bolus, Intramuscular (IM) injection, and Oral (tablet) routes. The total combined duration of use for all routes, including both injection and tablets, must not exceed 5 days.

Population & Route	Standard Multiple Dose	Maximum Daily Dose
Non-Elderly Adults (ge 50 kg)	30 mg IV/IM every 6 hours	120 mg
Elderly, Low-Weight, or Impaired	15 mg IV/IM every 6 hours	60 mg
Oral Continuation Therapy	10 mg every 4 to 6 hours	40 mg

Dosage must be reduced for patients aged 65 years or older, those weighing less than 50 kg (110 lbs), or those with moderately elevated serum creatinine.

---

Administration and Procedural Rules

1. Parenteral Administration: The IV bolus must be given over no less than 15 seconds, and IM injections should be administered slowly and deeply into the muscle.
2. Oral Timing: The oral tablet should not be given as an initial dose. Taking the oral tablet after a high-fat meal can result in decreased peak concentration.
3. Incompatibility: The injection should not be mixed with certain other solutions, such as morphine or promethazine, due to the risk of precipitation.

Research Evidence / Overview of Studies for Zerodol (Ketorolac Tromethamine)

---

Evidence for Short-Term Management of Moderately Severe Acute Pain

The most substantial body of research for Zerodol has been conducted in studies exploring short-term symptom changes related to acute pain. This includes Randomized Controlled Trials (RCTs) and large-scale reviews focused on acute, high-intensity pain, such as the post-operative setting. These studies monitored outcomes related to physical discomfort in adults who were observed during periods of heightened symptom activity.

The primary populations studied were adults (18-65 years) observed during periods of heightened symptom activity, frequently in post-surgical or post-procedure research contexts (e.g., orthopedic, abdominal, or general surgical pain). The findings describe patterns observed in the studies related to the use of rescue analgesic medication (such as opioids) by patients during the initial hours after the procedure, when compared to control groups.

---

Studies on Specific Acute Pain Contexts

Research has also explored how Zerodol was studied in specific, short-lived, high-intensity pain episodes that are conditions involving periods of heightened symptoms, such as acute back pain. In these contexts, studies often focused on comparing different methods of administration and their measured effects on the outcomes related to physical discomfort. The evidence contributes to understanding symptom patterns in these specific, often urgent, research scenarios.

---

Duration of Evidence and Follow-Up in Studies

The design of the research for Zerodol is centered exclusively on short-term use. This means that follow-up durations were limited, typically lasting only a few hours to a maximum of five days, consistent with the limits studied for systemic administration. The current evidence base provides insight into the immediate changes observed during the acute, limited period of use. However, there is limited information for long-term outcomes that may result from extended use.

---

Understanding the Research Gaps and Uncertainties

While many studies have explored the initial observations of Zerodol, there are still areas where the certainty remains low or the evidence is incomplete. Long-term effects are not fully established because the trials were designed for short-term observation only. The results apply only to the populations studied and may not reflect patterns across a wider, diverse group of people. Furthermore, comparative evidence is lacking for every potential comparison drug, as findings were mixed across the different non-opioid medications it was studied for comparison against.

Common questions about Zerodol (FAQ)

Q: What is Zerodol?

A: Zerodol is the brand name for a medicine containing the active ingredient Aceclofenac. It belongs to a class of drugs called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It works by blocking the action of certain chemical messengers (prostaglandins) in the body that cause pain and inflammation.

Q: What is Zerodol used for?

A: Zerodol (Aceclofenac) is generally used to relieve pain and inflammation associated with conditions such as:

• Osteoarthritis (wear-and-tear arthritis)
• Rheumatoid arthritis (an autoimmune disorder)
• Ankylosing spondylitis (a form of arthritis that primarily affects the spine)

Q: How should I take Zerodol?

A: Always take Zerodol exactly as your healthcare provider or pharmacist has instructed. It is typically taken by mouth. To minimize the chance of stomach upset or irritation, it is usually recommended to take this medication with food or milk.

Q: What are the common side effects of Zerodol?

A: Like all medicines, Zerodol can cause side effects, though not everybody gets them. Gastrointestinal issues are among the most common, including:

• Stomach pain (abdominal pain)
• Indigestion (dyspepsia)
• Nausea
• Diarrhea

Less common but serious side effects can affect the heart, circulation, and stomach lining. If you experience unusual bleeding, severe stomach pain, or chest pain, seek immediate medical attention.

Q: Can I take Zerodol if I am pregnant?

A: Zerodol (Aceclofenac) is generally not recommended during pregnancy, especially during the third trimester, as it may harm the developing baby or cause problems during delivery. If you are pregnant, planning to become pregnant, or breastfeeding, you should discuss the risks and benefits with a healthcare provider before using this medicine.

Q: Does Zerodol interact with other medications?

A: Yes, Zerodol can interact with various other medicines. It's important to tell your healthcare provider about all the prescription and non-prescription medicines, vitamins, and herbal supplements you are currently taking. Particular caution is needed if you are taking:

• Other NSAIDs or Aspirin
• Blood thinners (anticoagulants), such as Warfarin
• Diuretics (water pills)
• Corticosteroids
• Lithium
• Methotrexate

These interactions can increase the risk of side effects or change how the medications work.

How to Store and Dispose of Zerodol (Ketorolac Tromethamine)

Official regulatory labeling dictates specific storage and disposal procedures to maintain product integrity and safety.

---

Storage Requirements

Zerodol (all forms) must be stored at Controlled Room Temperature, typically 20 C to 25 C. All products must be protected from light and excess moisture. The injectable solution must not be refrigerated or frozen. Tablets and ophthalmic solutions must be kept in their tightly closed container.

---

Handling and Safety

It is a mandatory requirement to store the medicine out of the sight and reach of children and pets. For the injectable solution, any unused portion from a single-use container must be discarded immediately.

---

Disposal Instructions

Unused or expired Zerodol must be disposed of properly in accordance with local requirements. The preferred method is using an authorized drug take-back program. If not available, the medicine should be secured in the household trash as recommended by government guidelines, and it must not be flushed down the toilet.